

Wuliangye Yibin (000858.SZ): First Take: Solid delivery in 4024/1025 amid channel reform; 2025 growth target in line with macro growth;

Wuliangye reported FY24 and 1Q25 results on Apr 25th. In 2024, the company reported revenue of Rmb89.2bn, up 7.1% yoy, and net profit of Rmb31.9bn, up 5.4% yoy, above GSe of 4%/3% yoy, with an implied NPM of 35.7%, down -0.6ppt yoy, with margin contraction mainly from enhanced investments offsetting GPM expansion. Implied 4024 sales were Rmb21.3bn, up 2.5% yoy, and net profit was Rmb6.9bn, down 6.2% yoy, with an NPM of 32.6%, better than lowered expectation of sales declines in 4Q24 (GSe of -10%/-15% sales/NP declines in 4Q24). 1Q25 sales came in at Rmb36.9bn, up 6.1% yoy, and net profit was Rmb14.9bn, up 5.8% yoy, both slightly higher than GSe of 5%/5% yoy. The implied 1Q25 NPM was 40.2%, -0.1ppt yoy. **Combined 4Q24 + 1Q25** sales/NP growth was +4.7%/+1.7% yoy, +5%/+4% vs. GSe, respectively. Customer advance at end-1Q25 was Rmb10.2bn, up strongly 101% yoy. Cash from selling goods was at Rmb38.2bn, up 76% yoy in 1Q25. Dividend: The company announced final cash dividend of Rmb3.169 per share (pre-tax) in 2024. Considering an interim dividend distributed for 2024 of Rmb2.576 per share, the total payout ratio reached 70% (vs. 60% in 2023) and dividend yield of 4.5%.

2025 guidance: The company aims to achieve total sales growth yoy in line with the growth of macro economic indicators in 2025 (GSe GDP growth of 4.0% yoy for 2025), and improve both brand value and market shares.

Our view: We see this result as a solid delivery amid the industry transition period, where company managed to achieve above GSe growth in both 2024/1Q25. **We maintain Buy-rating with compelling risk-reward in Wuliangye** (trading at c.15x 2025 P/E, towards the lower bound of our China spirits coverage, with a c.5% dividend yield in 2025.

Leaf Liu

+852-3966-4169 | leaf.liu@gs.com Goldman Sachs (Asia) L.L.C.

Hongda Zhong

+852-2978-2300 | hongda.zhong@gs.com Goldman Sachs (Asia) L.L.C.

Christina Liu

+852-2978-6983 | christina.liu@gs.com Goldman Sachs (Asia) L.L.C.

Julia Mu


+852-2978-1219 | julia.mu@gs.com Goldman Sachs (Asia) L.L.C.

Valerie Zhou

+852-2978-0820 | valerie.zhou@gs.com Goldman Sachs (Asia) L.L.C.

2024 results highlight:

■ **Sales:** Spirits sales were up 8.7% yoy, on 1.8% volume growth and 6.8% ASP expansion, mainly on product mix improvement in series spirits segment.



- □ **By channel**, direct sales grew by 12.9% yoy and accounted for 41.4% of total spirits sales, up 1.5ppt yoy. Sales in wholesale channels grew by 6.0% yoy.
- □ **By region,** sales in east/south region grew by 9.8%/12.7% yoy in 2024, while north region saw 4.0% yoy sales decline.
- □ **Distributors and specialty stores**: The number of distributors was up 327 yoy to 3,711 (including 2,652 Wuliangye distributors and 1,059 series spirits distributors), and the number of specialty stores was up 124 yoy to 1,786 in end-2024.
- Margin: GPM was up 1.3ppt yoy at 77.1%, on ASP increases, product mix improvement and active cost control initiatives. Selling expense ratio was up 2.6ppt to 12.0% due to higher channel spending to enhance distributors' confidence, and admin expense ratio was slightly up 0.1ppt yoy at 4.4%. Sales tax as % of revenue was down -0.4ppt yoy to 14.6%. NPM was down -0.6ppt to 35.7% in 2024.
- Implied 4Q24 sales were up 2.5% yoy while net profit was down -6.2% yoy, with an implied NPM of 32.6%, down -3.0ppt yoy mainly due to a 6.1ppt selling expense ratio increase yoy, partly offset by lower sales tax yoy and higher GPM in the quarter.
- **Customer advances** stood at Rmb11.7bn in end of 2024, up 70% yoy. Cash from selling goods in 2024 was Rmb24.0bn, down -38% yoy.

1025 results:

- Sales reached Rmb36.9bn, up 6.1% yoy and net profit was Rmb14.9bn, up 5.8%.
- Margin: 1025 GPM was at 77.7%, down -0.7ppt yoy. Selling expense ratio was down -1.0ppt yoy to 6.5%, and admin expense ratio was down -0.2ppt yoy to 3.1%. NPM was at 40.2%, slightly down -0.1ppt yoy.
- Cash flow and B/S: Customer advances stood at Rmb10.2bn in end of 1Q25, up 101% yoy, accounting for 61% of our 2Q25E sales estimates. Note receivables was at Rmb19.3bn, down -31% yoy, indicating higher cash proportion in the prepayment. Adjusted sales (factoring in customer advances) were up 7% yoy. Cash from selling goods were at Rmb38.2bn, up 76% yoy on lower portion of note receivables in the prepayment.

Recent update: The wholesale price of the 8th Common Wuliangye recently weakened

and lowered to Rmb925~930 per bottle from previous c.Rmb940 with shipment resuming post the strict shipment control during LNY period. Company's key growth target is to drive Common Wuliangye's growth in white space regions/markets and further develop its 1618 and low degree 39C Wuliangye SKUs esp. in banquet scenarios. Wuliangye's prepayment pace is tracking at roughly 50% and channel inventory is c.1 month.

Operating and financial data summary

Exhibit 1: Half-year analysis of operating data

lalf-year analysis of operating data (added)	1H22	2H22	1H23	2H23	1H24	2H24
ogs						
Overall	9,514	8,664	10,568	9,589	11,466	8,995
High-end Wuliangye	4,356	3,079	4,642	3,747	5,217	3,594
Low-to-mid-end Wuliangye	2,632	2,177	2,642	2,794	2,986	2,990
Others	2,527	3,409	3,284	3,048	3,263	2,41
Init COGS						
Liquor	97,248	95,018	78,556	98,532	104,698	78,728
High-end Wuliangye	233,692	217,893	215,027	219,505	215,635	209,000
Low-to-mid-end Wuliangye	49,458	52,857	37,137	56,658	55,137	45,009
oy						
Liquor	72%	10%	-19%	4%	33%	-20%
High-end Wuliangye	1%	-15%	-8.0%	0.7%	0.3%	-4.89
Low-to-mid-end Wuliangye	72%	24%	-24.9%	7.2%	48.5%	-20.6%
P.						
Overall	31,708	24,082	34,938	28,176	39,182	29,532
High-end Wuliangye	27,617	20,283	30,537	23,878	33,988	25,076
Low-to-mid-end Wuliangye	3,908	3,511	4,072	4,136	4,920	4,355
Others	183	287	330	162	274	100
% Overall						
High-end Wuliangye	87%	84%	87%	85%	87%	85%
Low-to-mid-end Wullangye	12%	15%	12%	15%	13%	15%
Others	1%	1%	1%	1%	1%	0%
Curers	170	170	170	170	170	0.7
oy Ower!!	15%	8%	10%	17%	12%	5%
Overall						
High-end Wuliangye	18%	9%	11%	18%	11%	5%
Low-to-mid-end Wuliangye	-3%	1%	4%	18%	21%	5%
Others	45%	45%	81%	-44%	-17%	-38%
РМ						
Overall	76.9%	73.5%	76.8%	74.6%	77.4%	76.7%
High-end Wuliangye	86.4%	86.8%	86.8%	86.4%	86.7%	87.5%
Low-to-mid-end Wuliangye	59.8%	61.7%	60.7%	59.7%	62.2%	59.3%
Others	6.8%	7.8%	9.1%	5.1%	7.8%	4.0%
iquor only	81.9%	81.9%	82.6%	81.1%	82.6%	81.7%
SP by channel GP						
Wholesale	17,768	14,022	19,329	16,866	21,992	16,423
Direct sales	13,757	9,773	15,279	11,146	16,916	13,006
% Liquor						
Direct sales	44%	41%	44%	40%	43%	44%
Wholesale	56%	59%	56%	60%	57%	56%
-	5576	00.70	55.5	55.5	51.76	3070
oy Wholesale	25%	-5%	9%	20%	14%	-3%
Direct sales	25% 5%	-5% 31%	9% 11%	20%	14%	-3% 17%
Direct sales	5%	31%	11%	14%	11%	17%
GPM						
Wholesale	78.3%	78.8%	79.5%	77.8%	79.7%	77.7%
Direct sales	86.9%	86.9%	86.9%	86.5%	86.7%	87.5%

Source: Company data

Exhibit 2: Wuliangye - Act vs. Est

Mary	Wuliangye	2021	2022	2023	2024	2024	202	4	1Q23	1Q24	2Q24	3Q24	4Q24	4Q24	4Q24	1	1Q25	1Q25	1Q2	5	1Q25+4	Q24	1Q25+4	Q24
Teal Spring 1732 0730 7642 0730 7642 0730 0740	Rmb mn		Actual		Actual	Estimate	Diff								Diff				Diff					yoy
May not glant 40 17 20 20 20 20 20 20 20 2									31,139	34,833	15,815	17,268	21,260	18,717	14%	3%	36,940	36,575	1%	6%	58,200	55,291	5%	5%
Mail and the wed Speit 12,000 12,001 15,201 14,001 15,00																								
Control Cont																								
Page and Signiff Volume (burst) 20.201 20.																								
Figure a Spirit ASP (Prohibotins) Figure 2 Figure 2 Figure 3 Figure	Others	4,477	6,406	6,825	6,048	7,371	-18%	-11%																
High and Sign ASP (Prohiboting)							6%	7%																
Post							-196	194																
Series sport ASP (Porkbottes) Vo. 1 15							-1,74	.,.																
Park 1974 1974 1974 1974 1974 1975	YoY	15%	-38%	28%	0%	-15%																		
Fig. 178							-11%	12%																
Processing Process P									499/	492/	400/	49/	98/	100/			60/	59/			E9/	00/		
Separate parameter 18/50 79/50							49/	00/							400/	49/			49/	69/			69/	E9/
Seles tax and and condorm 9,700 10749 12,532 13,041 12,979 ON 44% 4.459 4.879 12,979 ON 4.679 13,974																								
as % of revenue 4 48% 148% 159% 150% 150% 150% 150% 150% 150% 150% 150																								
Sales expresses 6.504 6,844 7709 10,802 9,410 149k 379k 2,112 2,682 8,487 759k 17,898 10,898 2,398 2,																								
Administrative expenses as of Forewhere by 10,220 Amount 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,	Sales expense	6,504	6,844			9,410			2,112	2,624	2,742	2,422	2,904				2,408				5,311	4,420		
Come OP 10,000 34,80 34,84 41,000 45,84	as % of revenue							2.6ppt		7.5%						6.1ppt	6.5%		-1.1ppt	-1.0ppt			1.1ppt	
Concord Conc																								
No. Processing expenses 10 28 5 60 0 0 1.0																								
Come OP Margin 46, 1% 47, 47, 47, 48, 40, 58,							2%	5%							12%	-7%			1%	6%			4%	1%
Other operating expenses																								
Net Harmides expenses (1732) (2020) (2473) (2884) (2886) -4% 175% (814) (720) (881) (719) (714) (808) -15% 8 5% (699) (270) -9% -9% (1372) (1509) -175% 1% (1884) (47.0%														53.3%						
Investment gain/flosses 97 93 58 75 88 31% 37% 376 88 31% 37% 376 88 31% 37% 376 88 31% 376 88 49% 44% 50 0 0 n.m. n.m. n.m. n.m. 40 98 44% 100 100 100 100 100 100 100 100 100 10				5														0						
Nen-operaling income 286 229 377 311 377 45% 175 186 77 150 45% 44% 52 2 5 50 20 63 77% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 20 2 2.71% 55% 2.71% 2.71% 55% 2.71% 2.7												(/19)												
Non-operating expenses 154 110 130 77 150 49% 44% 52 2 5 50 20 93 79% 59% 20 2 2. m.m. n.m. 46 95 59% 99%												20												
Pre-base profit (income before last) 24,603 7,104 4,1913 4,4193 3,133 25,505 5,405 4,1913 4,1																								
Process 1,13 1,33 1,33 1,33 2,35 1,34 3,35																		-						
Net Income 24.507 27.971 31.502 31.93 32.906 Monthly Interesting 32.977 28.907 38.907																								
Month Month Month Mark Mont							296																	
Note Inclinate attributable to parent 23,377 26,681 30,211 31,883 31,235 51,583																								
Vigor 17% 14% 13% 5% 35%								5%																2%
Expr Bit S CF Stems 2022 2023 2024																								
Page Big C/S Interes 2011 2022 2023 2024																					37.4%	38.0%	-0.5ppt	-1.1ppt
Class (mer Advance at 13,059 12,379 6,864 11,809 5,536 5,477 8,158 7,072 11,800 10,169 A 15 of ment (quater safes) 5,536 5,477 8,158 7,072 11,800 10,169 10,169 15,552 61,532 15,567 15,307 25,346 15,552 15,567 15,307 25,346 15,552 15,567 15,307 25,346 15,552 15,567 15,307 25,346 15,552 15,567 15,307 25,346 15,552 15,567 15,307 25,346 15,552 15,567 15,307 25,346 15,552 15,567 15,307 15,312 15,552 15,567 15,307 15,312 15,552 15,567 15,307 15,312 15,552 15,567 15,307 15,312 15,552 15,567 15,307 15,312 15,552 15,567 15,307 15,312 15,552 15,567 15,307 15,312 15,552 15,567 15,312 15,552 15,567 15,312 15,552 15,567 15,312 15,552 15,567 15,312 15,552 15,567 15,312 15,552 15,567 15,312 15,552 15,567 15,312 15,552 15,567 15,312 15,552 15,567 15,312 15,552 15,567 15,312 15,552 15,567 15,312 15,552 15,557 15,312 15,552 15,567 15,567 15,567 15,567 15,567 15,552 15,567 15,567 15,567 15,567 15,567 15,567 15,552 15,567	EPS (RMB)	6.0	6.9	7.8	8.2	8.0	2%	5%	3.2	3.6	1.3	1.5	1.8	1.6	10%	-6%	3.8	3.8	1%	6%				
Class (mer Advance at 13,059 12,379 6,864 11,809 5,536 5,477 8,158 7,072 11,800 10,169 A 15 of ment (quater safes) 5,536 5,477 8,158 7,072 11,800 10,169 10,169 15,552 61,532 15,567 15,307 25,346 15,552 15,567 15,307 25,346 15,552 15,567 15,307 25,346 15,552 15,567 15,307 25,346 15,552 15,567 15,307 25,346 15,552 15,567 15,307 25,346 15,552 15,567 15,307 25,346 15,552 15,567 15,307 15,312 15,552 15,567 15,307 15,312 15,552 15,567 15,307 15,312 15,552 15,567 15,307 15,312 15,552 15,567 15,307 15,312 15,552 15,567 15,307 15,312 15,552 15,567 15,307 15,312 15,552 15,567 15,312 15,552 15,567 15,312 15,552 15,567 15,312 15,552 15,567 15,312 15,552 15,567 15,312 15,552 15,567 15,312 15,552 15,567 15,312 15,552 15,567 15,312 15,552 15,567 15,312 15,552 15,567 15,312 15,552 15,567 15,312 15,552 15,557 15,312 15,552 15,567 15,567 15,567 15,567 15,567 15,552 15,567 15,567 15,567 15,567 15,567 15,567 15,552 15,567	Key R/S & CFS items	2021	2022	2023	2024				1023	1024	2024	3024	4024	1025										
As for first quarter sales As 50 first quarter sales As 50 first quarter sales As 50 first quarter sales Cachi from spling goods B 9 53 B 171 105,550 11,899 B 28,837 2 12,809 B																								
Calculational adjusted total sales Cash from selling goods 8 0.593 8 1.71 105.390 101.899 28.03 3 2.759 18.597 82.11 24.09 38.234 Note receivables receivables financing leventury Livertury Livertu	As % of next quarter sales								39%	32%	47%													
Note recentables recentables financing (25,083	33,225	18,567	16,307	25,346	35,592										
Inventory 14,015 15,981 17,388 18,234 18,005 18,286 18,287 17,538 18,224 17,035 VeV Customer Advance 62% 5% 45% 70% 53% 9% 124% 79% 70% 101% Calculated adjusted tolal sales 31% 32% 46% 69% 99% 7% Cash from selling goods 29% 1% 29% 3-% 109% 52% 99% 19% 50% 19% 38% 79% 100% 100% 100% 100% 100% 100% 100% 10	Cash from selling goods	80,953	81,771	105,350	101,869				28,637	21,769	27,879	28,211	24,009	38,234										
YoY Same Advance 52% -5% -45% 70% 53% -9% 124% 79% 70% 101% Class dated adjusted total sales 31% 32% 46% -9% 7% Cash from selling goods 29% 13% 33% 108% 24% 89% 19% 78% Mole receivables from adding -8% 5% 25% 43% 43% 39% 31%	Note receivables + receivables financi	ng							26,671	28,109	19,580	7,590	19,577	19,312										
Calculated adjusted total sales 31% 32% 48% 49% 7% Cash from selling groots 29% 1% 29% 3% 108% 25% 93% 19% 38% 78% 19% 38% 78% 19% 38% 78% 19% 38% 78% 19% 38% 78% 19% 38% 78% 19% 38% 78% 19% 38% 78% 19% 38% 78% 19% 38% 78% 19% 38% 78% 19% 38% 78% 19% 38% 19% 38% 19% 38% 19% 38% 19% 19% 19% 19% 19% 19% 19% 19% 19% 19		14,015	15,981	17,388	18,234				16,065	16,286	16,847	17,536	18,234	17,035										
Cash from selling goods 29% 1% 29% -3% 109% 2-5% 93% 19% 39% 79% Note receivables receivables filtrating 4.8 25% -25% 43% 93% 13%	Customer Advance	52%	-5%	-45%	70%				53%	-9%	124%	79%	70%	101%										
Note receivables + receivables financing -8% 5% -23% -63% 39% -31%	Calculated adjusted total sales																							
			1%	29%	-3%																			
Inventory 6% 14% 9% 5% 16% 1% 5% 12% 5% 5%																								
	Inventory	6%	14%	9%	5%				16%	1%	5%	12%	5%	5%										

Source: Company data, Goldman Sachs Global Investment Research

Price Target Risks and Methodology - Wuliangye Yibin

Valuation methodology: Our 12m TP of Rmb166 is based on a 19.5x 2026E P/E discounted back to end-2025. Our target P/E is benchmarked to the company's full cycle average P/E in 2012-2023. We are Buy-rated.

Key downside risks: 1) A potential consumption tax rate hike; 2) Potential threats from Moutai-flavor brands; 3) Intensifying competition in high-end spirits.

000858.SZ	12m Price	e Target: Rmb166.00	Price: Rmb	129.05	Upside: 28.6%			
Buy		GS Forecast						
			12/23	12/24E	12/25E	12/26E		
	Market cap:	Revenue (Rmb mn)	83,272.1	86,632.1	91,482.2	98,641.9		
Rmb500	.9bn / \$68.7bn	EBITDA (Rmb mn)	39,731.2	41,026.2	43,548.6	47,605.5		
	nterprise value:	EPS (Rmb)	7.78	8.05	8.57	9.39		
	5.6bn / \$51.5bn	P/E (X)	22.1	16.0	15.0	13.7		
3m ADTV: Rmb2.8		P/B (X)	5.1	3.6	3.4	3.1		
Chi C.	China	Dividend yield (%)	2.7	4.4	4.7	5.1		
Cnina Cor	nsumer Staples M&A Rank: 3	N debt/EBITDA (ex lease,X)	(2.9)	(3.2)	(3.3)	(3.3)		
Leases incl. in net		CROCI (%)	24.5	23.1	22.8	23.0		
Leases IIIci. III liet	debt & Ev: . No	FCF yield (%)	5.8	6.4	7.0	7.6		
			9/24	12/24E	3/25E	6/25E		
		EPS (Rmb)	1.51	1.62	3.78	1.37		

Source: Company data, Goldman Sachs Research estimates, FactSet. Price as of 25 Apr 2025 close.

Disclosure Appendix

Reg AC

We, Leaf Liu, Hongda Zhong, Christina Liu, Julia Mu and Valerie Zhou, hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs' Global Investment Research division.

GS Factor Profile

The Goldman Sachs Factor Profile provides investment context for a stock by comparing key attributes to the market (i.e. our universe of rated stocks) and its sector peers. The four key attributes depicted are: Growth, Financial Returns, Multiple (e.g. valuation) and Integrated (a composite of Growth, Financial Returns and Multiple). Growth, Financial Returns and Multiple are calculated by using normalized ranks for specific metrics for each stock. The normalized ranks for the metrics are then averaged and converted into percentiles for the relevant attribute. The precise calculation of each metric may vary depending on the fiscal year, industry and region, but the standard approach is as follows:

Growth is based on a stock's forward-looking sales growth, EBITDA growth and EPS growth (for financial stocks, only EPS and sales growth), with a higher percentile indicating a higher growth company. **Financial Returns** is based on a stock's forward-looking ROE, ROCE and CROCI (for financial stocks, only ROE), with a higher percentile indicating a company with higher financial returns. **Multiple** is based on a stock's forward-looking P/E, P/B, price/dividend (P/D), EV/EBITDA, EV/FCF and EV/Debt Adjusted Cash Flow (DACF) (for financial stocks, only P/E, P/B and P/D), with a higher percentile indicating a stock trading at a higher multiple. The **Integrated** percentile is calculated as the average of the Growth percentile, Financial Returns percentile and (100% - Multiple percentile).

Financial Returns and Multiple use the Goldman Sachs analyst forecasts at the fiscal year-end at least three quarters in the future. Growth uses inputs for the fiscal year at least seven quarters in the future compared with the year at least three quarters in the future (on a per-share basis for all metrics).

For a more detailed description of how we calculate the GS Factor Profile, please contact your GS representative.

M&A Rank

Across our global coverage, we examine stocks using an M&A framework, considering both qualitative factors and quantitative factors (which may vary across sectors and regions) to incorporate the potential that certain companies could be acquired. We then assign a M&A rank as a means of scoring companies under our rated coverage from 1 to 3, with 1 representing high (30%-50%) probability of the company becoming an acquisition target, 2 representing medium (15%-30%) probability and 3 representing low (0%-15%) probability. For companies ranked 1 or 2, in line with our standard departmental guidelines we incorporate an M&A component into our target price. M&A rank of 3 is considered immaterial and therefore does not factor into our price target, and may or may not be discussed in research.

Quantum

Quantum is Goldman Sachs' proprietary database providing access to detailed financial statement histories, forecasts and ratios. It can be used for in-depth analysis of a single company, or to make comparisons between companies in different sectors and markets.

Disclosures

The rating(s) for Wuliangye Yibin is/are relative to the other companies in its/their coverage universe: Angel Yeast, Anhui Gujing Distillery Co., Budweiser APAC, Chacha Food Co., China Feihe Ltd., China Pet Foods, China Resources Beer, China Resources Beverage, Chongqing Brewery, Eastroc Beverage, Foshan Haitian Flavouring & Food, Fu Jian Anjoy Foods Co., Fuling Zhacai, Gambol Pet Group Co., Jiangsu Hengshun Vinegar, Jiangsu King's Luck Brewery, Jiangsu Yanghe, Jiuqui Liquor, Jonjee Hi-Tech, Kweichow Moutai, Ligao Foods, Luzhou Laojiao, Mengniu Dairy, Nongfu Spring, Petpal Pet Nutrition Technology, Qianhe Condiment and Food, Qianweiyangchu, Sanquan Foods, Shanghai Bairun, Shanxi Xinghuacun Fen Wine, Sichuan Swellfun Co., Sichuan Teway Food Group, Three Squirrels, Tingyi, Tsingtao Brewery (A), Tsingtao Brewery (H), Uni-President China, Want Want China, Weizhixiang, Wuliangye Yibin, Yankershop Food, Yihai International Holding, Yili Industrial, ZJLD

Company-specific regulatory disclosures

The following disclosures relate to relationships between The Goldman Sachs Group, Inc. (with its affiliates, "Goldman Sachs") and companies covered by Goldman Sachs Global Investment Research and referred to in this research.

Goldman Sachs expects to receive or intends to seek compensation for investment banking services in the next 3 months: Wuliangye Yibin (Rmb129.05)

Goldman Sachs had an investment banking services client relationship during the past 12 months with: Wuliangye Yibin (Rmb129.05)


Distribution of ratings/investment banking relationships

Goldman Sachs Investment Research global Equity coverage universe

	F	ating Distribution	n		Investme	ent Banking Relat	ionships
	Buy	Hold	Sell	l '	Buy	Hold	Sell
Global	49%	34%	17%		63%	57%	42%

As of April 1, 2025, Goldman Sachs Global Investment Research had investment ratings on 3,016 equity securities. Goldman Sachs assigns stocks as Buys and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral. Such assignments equate to Buy, Hold and Sell for the purposes of the above disclosure required by the FINRA Rules. See 'Ratings, Coverage universe and related definitions' below. The Investment Banking Relationships chart reflects the percentage of subject companies within each rating category for whom Goldman Sachs has provided investment banking services within the previous twelve months.

Price target and rating history chart(s)



Regulatory disclosures

Disclosures required by United States laws and regulations

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage. **Analyst compensation:** Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. **Analyst as officer or director:** Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director or advisor of any company in the analyst's area of coverage. **Non-U.S. Analysts:** Non-U.S. analysts may not be associated persons of Goldman Sachs & Co. LLC and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with subject company, public appearances and trading securities held by the analysts.

Distribution of ratings: See the distribution of ratings disclosure above. **Price chart:** See the price chart, with changes of ratings and price targets in prior periods, above, or, if electronic format or if with respect to multiple companies which are the subject of this report, on the Goldman Sachs website at https://www.gs.com/research/hedge.html.

Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. Australia: Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of Global Investment Research of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client's objectives, financial situation or needs. A client should, before acting on any such advice, consider the appropriateness of the advice having regard to the client's own objectives, financial situation and needs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs' Australian Sell-Side Research Independence Policy Statement are available at: https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html. Brazil: Disclosure information in relation to CVM Resolution n. 20 is available at https://www.gs.com/worldwide/brazil/area/gir/index.html. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 20 of CVM Resolution n. 20, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. Canada: This information is being provided to you for information purposes only and is not, and under no circumstances should be construed as, an advertisement, offering or solicitation by Goldman Sachs & Co. LLC for purchasers of securities in Canada to trade in any Canadian security. Goldman Sachs & Co. LLC is not registered as a dealer in any jurisdiction in Canada under applicable Canadian securities laws and generally is not permitted to trade in Canadian securities and may be prohibited from selling certain securities and products in certain jurisdictions in Canada. If you wish to trade in any Canadian securities or other products in Canada please contact Goldman Sachs Canada Inc., an affiliate of The Goldman Sachs Group Inc., or another registered Canadian dealer. Hong Kong: Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. India: Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst - SEBI Registration Number INH000001493, 951-A, Rational House, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India, Corporate Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Goldman Sachs (India) Securities Private Limited compliance officer and investor grievance contact details can be found at this link: https://publishing.gs.com/disclosures/hedge.html - /general/equity. Japan: See below. Korea: This research, and any access to it, is intended only for 'professional investors" within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. New Zealand: Goldman Sachs New Zealand Limited and its affiliates are neither "registered banks" nor "deposit takers" (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for "wholesale clients" (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at:

https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html. Russia: Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. Singapore: Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. Taiwan: This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. United Kingdom: Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

European Union and United Kingdom: Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) (2016/958) supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council (including as that Delegated Regulation is implemented into United Kingdom domestic law and regulation following the United Kingdom's departure from the European Union and the European Economic Area) with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at https://www.gs.com/disclosures/europeanpolicy.html which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

Japan: Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan Type II Financial Instruments Firms Association, The Investment Trusts Association, Japan, and Japan Investment Advisers Association. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

Ratings, coverage universe and related definitions

Buy (B), Neutral (N), Sell (S) Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy or Sell on an Investment List is determined by a stock's total return potential relative to its coverage universe. Any stock not assigned as a Buy or a Sell on an Investment List with an active rating (i.e., a stock that is not Rating Suspended, Not Rated, Early-Stage Biotech, Coverage Suspended or Not Covered), is deemed Neutral. Each region manages Regional Conviction Lists, which are selected from Buy rated stocks on the respective region's Investment Lists and represent investment recommendations focused on the size of the total return potential and/or the likelihood of the realization of the return across their respective areas of coverage. The addition or removal of stocks from such Conviction Lists are managed by the Investment Review Committee or other designated committee in each respective region and do not represent a change in the analysts' investment rating for such stocks.

Total return potential represents the upside or downside differential between the current share price and the price target, including all paid or anticipated dividends, expected during the time horizon associated with the price target. Price targets are required for all covered stocks. The total return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.

Coverage Universe: A list of all stocks in each coverage universe is available by primary analyst, stock and coverage universe at https://www.gs.com/research/hedge.html.

Not Rated (NR). The investment rating, target price and earnings estimates (where relevant) are removed pursuant to Goldman Sachs policy when Goldman Sachs is acting in an advisory capacity in a merger or in a strategic transaction involving this company, when there are legal, regulatory or policy constraints due to Goldman Sachs' involvement in a transaction, and in certain other circumstances. Early-Stage Biotech (ES). An investment rating and a target price are not assigned pursuant to Goldman Sachs policy when this company neither has a drug, treatment or medical device that has passed a Phase II clinical trial nor a license to distribute a post-Phase II drug, treatment or medical device. Rating Suspended (RS). Goldman Sachs Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for determining an investment rating or target price. The previous investment rating and target price, if any, are no longer in effect for this stock and should not be relied upon. Coverage Suspended (CS). Goldman Sachs has suspended coverage of this company. Not Covered (NC). Goldman Sachs does not cover this company.

Global product; distributing entities

Goldman Sachs Global Investment Research produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Public Communication Channel Goldman Sachs Brazil: 0800 727 5764 and / or contatogoldmanbrasil@gs.com. Available Weekdays (except holidays), from 9am to 6pm. Canal de Comunicação com o Público Goldman Sachs Brasil: 0800 727 5764 e/ou contatogoldmanbrasil@gs.com. Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9h às 18h; in Canada by Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman Sachs & Co. LLC. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom.

Goldman Sachs International ("GSI"), authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA, has approved this research in connection with its distribution in the United Kingdom.

European Economic Area: GSI, authorised by the PRA and regulated by the FCA and the PRA, disseminates research in the following jurisdictions within the European Economic Area: the Grand Duchy of Luxembourg, Italy, the Kingdom of Belgium, the Kingdom of Denmark, the Kingdom of Norway, the Republic of Finland and the Republic of Ireland; GSI - Succursale de Paris (Paris branch) which is authorised by the French Autorité de contrôle prudentiel et de resolution and the Autorité des marches financiers ("AMF") disseminates research in France; GSI - Succursal en España (Madrid branch) authorized in Spain by the Comisión Nacional del Mercado de Valores disseminates research in the Kingdom of Spain; GSI - Sweden Bankfilial (Stockholm branch) is authorized by the SFSA as a "third country branch" in accordance with Chapter 4, Section 4 of the Swedish Securities and Market Act (Sw. lag (2007:528) om värdepappersmarknaden) disseminates research in the Kingdom of Sweden; Goldman Sachs Bank Europe SE ("GSBE") is a credit institution incorporated in Germany and, within the Single Supervisory Mechanism, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research

in the Federal Republic of Germany and those jurisdictions within the European Economic Area where GSI is not authorised to disseminate research and additionally, GSBE, Copenhagen Branch filial af GSBE, Tyskland, supervised by the Danish Financial Authority disseminates research in the Kingdom of Denmark; GSBE - Sucursal en España (Madrid branch) subject (to a limited extent) to local supervision by the Bank of Spain disseminates research in the Kingdom of Spain; GSBE - Succursale Italia (Milan branch) to the relevant applicable extent, subject to local supervision by the Bank of Italy (Banca d'Italia) and the Italian Companies and Exchange Commission (Commissione Nazionale per le Società e la Borsa "Consob") disseminates research in Italy; GSBE - Succursale de Paris (Paris branch), supervised by the AMF and by the ACPR disseminates research in France; and GSBE - Sweden Bankfilial (Stockholm branch), to a limited extent, subject to local supervision by the Swedish Financial Supervisory Authority (Finansinpektionen) disseminates research in the Kingdom of Sweden.

General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by Global Investment Research. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (https://www.sipc.org).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

The analysts named in this report may have from time to time discussed with our clients, including Goldman Sachs salespersons and traders, or may discuss in this report, trading strategies that reference catalysts or events that may have a near-term impact on the market price of the equity securities discussed in this report, which impact may be directionally counter to the analyst's published price target expectations for such stocks. Any such trading strategies are distinct from and do not affect the analyst's fundamental equity rating for such stocks, which rating reflects a stock's return potential relative to its coverage universe as described herein.

We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research, unless otherwise prohibited by regulation or Goldman Sachs policy.

The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.

Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at https://www.theocc.com/about/publications/character-risks.jsp and <a href="https://www.theocc.com/about/publications/character-risks.jsp and <a href="https://www.theo

Differing Levels of Service provided by Global Investment Research: The level and types of services provided to you by Goldman Sachs Global Investment Research may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts' fundamental analysis available on our internal client websites be delivered to them electronically through data requity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to https://research.gs.com.

Disclosure information is also available at https://www.gs.com/research/hedge.html or from Research Compliance, 200 West Street, New York, NY 10282

© 2025 Goldman Sachs.

You are permitted to store, display, analyze, modify, reformat, and print the information made available to you via this service only for your own use. You may not resell or reverse engineer this information to calculate or develop any index for disclosure and/or marketing or create any other derivative works or commercial product(s), data or offering(s) without the express written consent of Goldman Sachs. You are not permitted to publish, transmit, or otherwise reproduce this information, in whole or in part, in any format to any third party without the express written consent of Goldman Sachs. This foregoing restriction includes, without limitation, using, extracting, downloading or retrieving this information, in whole or in part, to train or finetune a machine learning or artificial intelligence system, or to provide or reproduce this information, in whole or in part, as a prompt or input to any such system.